Pregabalin 300mg for Kidney Stones

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
University of Missouri-Columbia, Columbia, MOKidney Stones+3 MorePregabalin 300mg - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether the drug pregabalin can reduce the need for pain medication after ureteroscopy with stent placement, by giving it to patients before surgery. The trial is double-blinded, meaning neither the patients nor the staff will know who is receiving the drug or the placebo until after the study is completed.

Eligible Conditions
  • Kidney Stones
  • Addiction
  • Postoperative Pain
  • Opioid Use Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Within the first 30 days post-operation

Hour 1
Proportion of patients reporting nausea or vomiting
Visual analog scale of pain score
Watson clock drawing test score
In the pre-operative area before medication administration
Baseline Watson clock drawing test score
Baseline visual analog scale of pain score
Day 30
Number of serious adverse events
Number of unplanned healthcare interactions
Oral morphine equivalents of opioids prescribed
Proportion of patients with narcotic prescription

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Pregabalin 300mg
60%Dry mouth
30%Pain
10%Increased appetite
10%Somnolence
10%Fatigue
10%Dizziness
10%Confusion
10%Blurred vision
10%Back pain
This histogram enumerates side effects from a completed 2020 Phase 3 trial (NCT03927781) in the Pregabalin 300mg ARM group. Side effects include: Dry mouth with 60%, Pain with 30%, Increased appetite with 10%, Somnolence with 10%, Fatigue with 10%.

Trial Design

2 Treatment Groups

Pregabalin 300mg
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

200 Total Participants · 2 Treatment Groups

Primary Treatment: Pregabalin 300mg · Has Placebo Group · Phase 2 & 3

Pregabalin 300mg
Drug
Experimental Group · 1 Intervention: Pregabalin 300mg · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo oral tablet · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pregabalin
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: within the first 30 days post-operation

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor
332 Previous Clinical Trials
600,611 Total Patients Enrolled
Katie Murray, DOPrincipal Investigator - Assistant Professor
Ellis Fischel Cancer Center of University of Missouri, University of Missouri Hospital
2 Previous Clinical Trials
50 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many people have enrolled in this experiment?

"The information available on clinicaltrials.gov does suggest that this particular trial is recruiting patients at the moment. This trial was first posted on June 1st 2020 and received its latest update on October 20th 2021. The aim is to enroll 200 individuals from a single site." - Anonymous Online Contributor

Unverified Answer

What are the main indications for Pregabalin 300mg?

"Pregabalin 300mg is a medication typically used to treat fibromyalgia. However, it can also be an effective intervention for anxiety disorders, vitamin b12 deficiency, and issues with the spinal cord." - Anonymous Online Contributor

Unverified Answer

Are there still positions available for people who want to participate in this clinical trial?

"The clinical trial, which is currently looking for participants, was originally posted on 6/1/2020. The study has been updated as recently as 10/20/2021 according to the information available on clinicaltrials.gov" - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.